Eupraxia Pharmaceuticals Inc
EPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$202.22M
Close$
$1.44
76.1% downside
Current Fair Value
76.1% downsideOvervalued by 76.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $202.22 Million |
|---|---|
| Enterprise Value | $145.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.05 |
| Beta | 1.48 |
| Outstanding Shares | 56,712,624 |
Return
| Return on Equity | -38.60% |
|---|---|
| Return on Assets | -36.59% |
| Return on Invested Capital | -40.86% |
Valuation & Multiples
| P/E Ratio | -8.12 |
|---|---|
| PEG | -9.61 |
| Price to Sales | - |
| Price to Book Ratio | 3.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.57 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 7, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 55.02%▲ 13.71% |
|---|---|
| Total Invested | $156.50M▲ 50.17% |
| Investors Holding | 54▲ 19.00% |
ESG Score
No data